Recent News
Sirius Genomics Announces Change in Leadership
December 2009Sirius Genomics, announced today that Chris Wagner has been appointed President and Chief Executive Officer, replacing Dr. Brad Popovich. Dr. Popovich will continue as a member of Sirius Genomics Board and will continue to assist Mr. Wagner and the Company with the provision of strategic advice and support. The press release can be downloaded here.
Sirius Genomics Announces New Collaboration with Assistance Publique-Hopitaux de Paris
July 2009Sirius Genomics, a developer of pharmacogenomic diagnostics, announced that it has signed a collaborative agreement with the Assistance Publique-Hopitaux de Paris (AP-HP) to study genomic correlations in severe sepsis patients. The agreement focuses on the continued development of Sirius' pharmacogenomic diagnostic intended to assess responsiveness to recombinant human activated Protein C (sold by Eli Lilly and Company under the trademark Xigris ®) in patients with severe sepsis at high risk of death.
New Collaboration with Vanderbilt University
May 2009Sirius Genomics announced that it has signed a collaborative agreement with Vanderbilt University to study patients enrolled in Vanderbilt's Validating Acute Lung Injury biomarkers for Diagnosis (VALID) study. The agreement focuses on the continued development of Sirius' first pharmacogenomic diagnostic which is intended to assess responsiveness to recombinant human activated Protein C (sold by Eli Lilly and Company under the trademark Xigris ®).
Sirius highlighted in recent article on Xigris and personalized medicine
March 2009In the article, Sirius Genomics is mentioned as a company that could potentially help Eli Lilly resurrect its drug, recombinant activated Protein C also known as Xigris. The full article can be downloaded here.
Sirius selected as an Emerging Rocket Company for the second year
January 27, 2009The Emerging Rockets list profiles technology companies from multiple technology sectors with great potential for investment and market breakthroughs in the coming year. See the full list of Emerging Rockets Companies here.
New Collaboration with UK Critical Care Genomics Group
January 2009Sirius Genomics announced that it has signed a collaborative agreement with the United Kingdom Critical Care Genomics (UKCCG) Group. The agreement focuses on the continued development of Sirius' pharmacogenomic diagnostic for responsiveness to recombinant activated Protein C (sold by Eli Lilly and Company under the trademark Xigris ®).